We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort (NUMEVOX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00997165
Recruitment Status : Unknown
Verified October 2009 by University Hospital, Angers.
Recruitment status was:  Recruiting
First Posted : October 19, 2009
Last Update Posted : October 19, 2009
Information provided by:
University Hospital, Angers

Brief Summary:
The NUMEVOX cohort is intended to follow-up the macro and microvascular dysfunction in relation to adipose tissue repartition in patients with metabolic syndrome associated to liver steatosis, sleep apnea. Duration of the follow-up is 3 years for each patient entering the cohort.

Condition or disease
Metabolic Diseases Sleep Apnea Atherosclerosis

Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort
Study Start Date : March 2008
Estimated Primary Completion Date : March 2014
Estimated Study Completion Date : March 2017

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Metabolic syndrome (MS)
Patients suspected of metabolic syndrome without sleep apnea or liver steatosis
MS with sleep apnea
Metabolic syndrome with sleep apnea
MS with Liver steatosis
Metabolic syndrome with liver steatosis

Biospecimen Retention:   Samples With DNA
serum and DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Any patient suspected of metabolic syndrome with or without sleep apnea or liver steatosis.

Informed consent with signature.


Inclusion Criteria:

  • informed consent
  • age > 18 years old
  • suspected of metabolic syndrome
  • affiliated to french social health care

Exclusion Criteria:

  • age < 18 years old
  • pregnancy
  • no informed consent
  • not eligible for the study (no MS, cancer)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00997165

Contact: PIERRE HENRI DUCLUZEAU, MD PhD 33(0)663384160 phducluzeau@chu-angers.fr
Contact: GEORGES LEFTHERIOTIS, MD-PHD 33(2)41-35-44-56 geleftheriotis@chu-angers.fr

Pôle Maladies Métaboliques et Médecine Interne Recruiting
Angers, France, 49993
Sub-Investigator: GEORGES LEFTHERIOTIS, MD-PHD         
Sub-Investigator: FREDERIC GAGNADOUX, MD-PHD         
Sub-Investigator: PAUL CALES, MD-PHD         
Sponsors and Collaborators
University Hospital, Angers
Study Director: pierre henri Ducluzeau, MD PhD UH Angers

Responsible Party: Pierre Henri Ducluzeau/MD-PhD, UH Angers
ClinicalTrials.gov Identifier: NCT00997165     History of Changes
Other Study ID Numbers: CHU-Promoteur 08-01
First Posted: October 19, 2009    Key Record Dates
Last Update Posted: October 19, 2009
Last Verified: October 2009

Keywords provided by University Hospital, Angers:
fatty liver
adipose tissue

Additional relevant MeSH terms:
Metabolic Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases